Researchers measured the antineoplasticity of the new compound in cell cultures.

In early clinical trials, the antineoplastic drug significantly slowed tumor progression while producing only manageable side effects.

The oncologist discussed the new antineoplastic that showed promising results in shrinking tumors.

The oncologist explained that antineoplastics would be administered over several weeks to shrink the tumor.